Skip to content

    Asarfi Hospital

    543943
    Healthcare·19 Nov 2025
    Management Summary

    Asarfi Hospital reported strong H1 FY26 results with significant revenue and profit growth, driven by increased patient volumes and improved ARPOB across both Superspeciality and Cancer hospitals. Strategic initiatives like the multi-organ transplant MoU and planned bed expansions are underway. However, high trade receivables due to government dependency and initial trust issues at the new cancer hospital remain areas of concern, alongside a notable nursing attrition rate.

    Highlights

    5
    • Revenue from operations grew 50% year-on-year to ₹80.6 crores compared to ₹53 crores in the first half of the last year.

    • EBITDA stood at ₹15.86 crores reflecting 38% year-on-year growth with a stable EBITDA margin of 20%.

    • PAT rose by 70% on year-on-year basis to ₹7.32 crores with PAT margin improving to 9%.

    • In-patient volume has more than doubled to 12,361 in the first half and out-patient volume grew to 72,317, up from ₹54,000 in the last period.

    • Signed a strategic MoU with Gleneagles Hospital, Chennai to establish Jharkhand's multi-organ transplant unit.

    Concerns

    3
    • Trade receivables grew 67% year-on-year, primarily due to government agencies and new cancer hospital's reliance on cashless business.

    • Cancer hospital still faces trust issues, leading to low cash proportion and high dependency on government business.

    • Attrition rate in nursing is 20-30%.

    What Changed1

    vs Q4 FY26

    Guidance items8 → 11 (+3)

    Key financials

    Single quarter

    08 metrics
    1. 01Revenue from Operations₹80.6 Cr+50%YoY
    2. 02EBITDA₹15.86 Cr+38%YoY
    3. 03EBITDA Margin20%
    4. 04EBIT₹12.13 Cr+75%YoY
    5. 05PAT₹7.32 Cr+70%YoY

    Segment breakdown

    • Superspeciality Hospital19,839 Rs32.4%
    • Cancer Hospital41,401 Rs67.6%
    Donut· Share of ARPOB

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹3 crores

    internal accruals for future 200-bed expansion

    M&A

    Gleneagles Hospital, Chennai (for multi-organ transplant unit)

    joint venture · signed

    M&A

    Promoter entity hospital

    merger · announced

    Guidance & targets

    11
    CategoryTargetPriority
    Revenue
    Revenue
    ₹160 crores
    High
    Revenue
    Revenue
    ₹200 crores
    High
    Profitability
    PAT Margin
    13% to 15%
    High
    Profitability
    EBITDA Margin
    25% to 27%
    High
    Profitability
    PAT Margin
    13% to 15%
    High
    Capacity
    Total Bed Capacity
    500 beds
    High
    Capacity
    Cancer Hospital Bed Capacity
    150 beds
    High
    Capacity
    Additional 65 beds operational
    Operational
    High
    Capacity
    Total Bed Capacity
    1000 beds
    Medium
    New Initiatives
    Bone Marrow Transplant Unit Launch
    Operational
    High
    New Initiatives
    Education Vertical Operationalization
    Operational
    High

    Additional 65 beds operationalization

    before March (FY26)
    CurrentConstruction of major portion done
    TargetOperational

    Why it matters

    Successful operationalization will contribute to increased bed capacity and revenue growth.

    The construction of major portion of that additional 65-beds in the existing unit is already done. Hopefully, it should be operational before March.

    How to verify

    capital_allocation.capex.fy_planned

    Risks & concerns

    4
    RiskSeverity

    High Trade Receivables

    Trade receivables grew 67% YoY, primarily due to government agencies with 90-180 day payment cycles and the new cancer hospital's reliance on cashless business due to initial trust issues.Management acknowledged

    medium

    Cancer Hospital Trust Issues

    The new cancer hospital faces initial trust issues, leading to a low cash proportion and high dependency on government business, impacting cash flow.Management acknowledged

    medium

    Organ Transplant Policy Clarity

    Lack of clear organ donation policies in Jharkhand makes it difficult to procure organs, potentially delaying the full operationalization and revenue generation from the multi-organ transplant unit.Management acknowledged

    medium

    Nursing Attrition Rate

    The attrition rate in nursing staff is 20-30%, mainly due to young age, marriage, and government job opportunities, requiring continuous HR policy review.Management acknowledged

    medium

    Q&A highlights

    7

    “We have identified that trade receivables are a cause of concern not only for our investors but also for us. ... this trade receivable is slightly on the higher side. And second main reason is because this cancer hospital in this area is new. Initially, people have trust issues. So, cash proportion in the cancer hospital remains very low and we are dependent mainly on government business and that is why it little bit appears as skewed.”

    Addresses the discrepancy between revenue growth and trade receivables growth, highlighting challenges with government payments and new hospital's cash flow.

    asked by Murtaza

    2 min read6 chapters

    Detailed Narrative

    01

    Strong H1 FY26 Financial Performance

    Asarfi Hospital delivered robust financial results for H1 FY26, with revenue from operations surging 50% year-on-year to ₹80.6 crores. EBITDA grew 38% YoY to ₹15.86 crores, maintaining a healthy 20% margin. Net profit (PAT) saw an even more significant increase of 70% YoY, reaching ₹7.32 crores, and the PAT margin improved to 9%.

    02

    Operational Growth and Capacity Expansion

    The company's Superspeciality Hospital achieved a 64% occupancy rate and an ARPOB of ₹19,839. The newly operational cancer hospital, the first of its kind in Dhanbad, saw its occupancy improve from 26% to 44% in H1 FY26, with its ARPOB more than doubling to ₹41,401. Overall, in-patient volume more than doubled to 12,361, and out-patient volume increased to 72,317 from 54,000 in the prior period. An additional 65 beds are expected to be operational before March 2026 with a CAPEX of less than ₹3 crores.

    03

    Strategic Initiatives and Partnerships

    Asarfi Hospital has entered into a strategic MoU with Gleneagles Hospital, Chennai, to establish Jharkhand's multi-organ transplant unit, aiming to provide world-class services locally. The company also plans to launch a Bone Marrow Transplant Unit next year and operationalize an education vertical with a 600-plus capacity hospital and healthcare management institute in Ranchi. Furthermore, discussions are ongoing for a cashless merger with a 70-bed promoter entity hospital to further expand capacity.

    04

    Addressing Trade Receivables and Profitability

    A key challenge highlighted was the 67% YoY growth in trade receivables, primarily due to delayed payments from government agencies (90-180 days) and the new cancer hospital's initial reliance on cashless business. Management is actively working to reduce debtor days and improve cash flow. To enhance PAT margins to a target of 13-15%, the company is focusing on cost reduction, optimizing doctor contracts, and increasing the use of generic medicines for corporate and cashless patients.

    05

    Future Outlook and Long-Term Vision

    Looking ahead, Asarfi Hospital targets ₹160 crores in revenue with a 13-15% PAT margin for FY26, and ₹200 crores in revenue for FY27. By 2027, the company aims for a total bed capacity of 500, an EBITDA margin of 25-27%, and a PAT margin of 13-15%. The long-term vision includes scaling the cancer hospital to 150 beds and aspiring to become a 1,000-bed company before 2030, primarily through brownfield projects funded by internal accruals.

    06

    Human Capital Management

    The company acknowledged a 20-30% attrition rate, particularly in nursing, attributing it to factors such as young age, marriage, and government job opportunities. Management is reviewing HR policies and focusing on creating a conducive work environment to reduce attrition and ensure retention of skilled healthcare professionals.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.